Gut microbiome-targeted therapies for Alzheimer’s disease

25Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The advent of high­throughput ‘omics’ technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer’s disease (AD), a neurodegenerative disorder. Frequent bidirectional communications and mutual regulation exist between the gastrointestinal tract and the central nervous system through the gut-brain axis. A large body of research has reported a close association between the gut microbiota and AD development, and restoring a healthy gut microbiota may curb or even improve AD symptoms and progression. Thus, modulation of the gut microbiota has become a novel paradigm for clinical management of AD, and emerging effort has focused on developing potential novel strategies for preventing and/or treating the disease. In this review, we provide an overview of the connection and causal relationship between gut dysbiosis and AD, the mechanisms of gut microbiota in driving AD progression, and the successes and challenges of implementing available gut microbiome-targeted therapies (including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation) in preventive and/or therapeutic preclinical and clinical intervention studies of AD. Finally, we discuss the future directions in this field.

Cite

CITATION STYLE

APA

Zhang, T., Gao, G., Kwok, L. Y., & Sun, Z. (2023). Gut microbiome-targeted therapies for Alzheimer’s disease. Gut Microbes. Taylor and Francis Ltd. https://doi.org/10.1080/19490976.2023.2271613

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free